Virus	Туре	Evolutionary rate (10 ⁻³ sub/site/year)	Reference
HIV	Retrovirus	2.02 – 16.8	(1)
Poliovirus	+ssRNA	10.3	(2)
Influenza A	-ssRNA	1.43 - 1.16	(3)
SARS-CoV	+ssRNA	7.8	(4)
SARS-CoV-2	+ssRNA	0.8 - 6.58	(5)
Rotavirus	dsRNA	0.73	(6)
Hepatitis C virus	+ssRNA	0.48-0.91	(7)
MERS-CoV	+ssRNA	0.24	(4)

Table S1. Evolutionary rates of pathogenic RNA viruses

- I. M. Berry, R. Ribeiro, M. Kothari, G. Athreya, M. Daniels, H. Y. Lee, W. Bruno, T. Leitner, Unequal Evolutionary Rates in the Human Immunodeficiency Virus Type 1 (HIV-1) Pandemic: the Evolutionary Rate of HIV-1 Slows Down When the Epidemic Rate Increases. *Journal of Virology*. 81, 10625–10635 (2007).
- 2. J. Jorba, R. Campagnoli, L. De, O. Kew, Calibration of Multiple Poliovirus Molecular Clocks Covering an Extended Evolutionary Range. *J Virol.* **82**, 4429–4440 (2008).
- 3. D. Rejmanek, P. R. Hosseini, J. A. K. Mazet, P. Daszak, T. Goldstein, Evolutionary Dynamics and Global Diversity of Influenza A Virus. *Journal of Virology*. **89**, 10993–11001 (2015).
- M. F. Boni, P. Lemey, X. Jiang, T. T.-Y. Lam, B. W. Perry, T. A. Castoe, A. Rambaut, D. L. Robertson, Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nature Microbiology*. 5, 1408–1417 (2020).
- L. van Dorp, M. Acman, D. Richard, L. P. Shaw, C. E. Ford, L. Ormond, C. J. Owen, J. Pang, C. C. S. Tan, F. A. T. Boshier, A. T. Ortiz, F. Balloux, Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution*. 83, 104351 (2020).
- 6. Y. Fujii, Y. H. Doan, Y. Suzuki, T. Nakagomi, O. Nakagomi, K. Katayama, Study of Complete Genome Sequences of Rotavirus A Epidemics and Evolution in Japan in 2012–2014. *Front. Microbiol.* **10** (2019), doi:10.3389/fmicb.2019.00038.
- M. Yuan, T. Lu, C. Li, L. Lu, The Evolutionary Rates of HCV Estimated with Subtype 1a and 1b Sequences over the ORF Length and in Different Genomic Regions. *PLOS ONE*. 8, e64698 (2013).

Antibody	% Change in Binding Affinity for Optimal	
	Escape Mutant	
\$309	120%	
EY6A	155%	
S2A4	120%	
\$304	155%	
S2M11	117%	
B38	200%	
C105	178%	
P2B-2F6	141%	
CB6	151%	
CC12.1	200%	
CC12.3	200%	
CV30	200%	
Fab 2-4	178%	
COVA2-04	200%	
COVA2-39	200%	
S2H13	200%	
S2H14	200%	
S2E12	123%	
REGN10933	178%	
REGN10987	200%	

Table S2. Antibody escape mutants with highest ACE2 binding affinities.

 Table S3. Antibody structures used.

Antibody Name	Structure Type	Source
S309	Cryo-electron Microscopy and Crystal Structure	(1)
EY6A	Cryo-electron Microscopy and Crystal Structure	(2)
S2A4	Cryo-electron Microscopy and Crystal Structure	(3)
S304	Cryo-electron Microscopy and Crystal Structure	(3)
S2M11	Cryo-electron Microscopy	(4)
B38	Crystal Structure	(5)
C105	Cryo-electron Microscopy of complex. Crystal	(6)
	structure of antibody.	
P2B-2F6	Crystal Structure	(7)
CB6	Crystal Structure	(8)
CC12.1	Crystal Structure	(9)
CC12.3	Crystal Structure	(9)
CV30	Crystal Structure	(10)
Fab 2-4	Cryo-electron Microscopy	(11)
COVA2-04	Crystal Structure	(12)
COVA2-39	Crystal Structure	(12)
S2H13	Cryo-electron Microscopy	(3)
S2H14	Cryo-electron Microscopy and Crystal Structure	(3)
S2E12	Cryo-electron Microscopy of complex. Crystal structure of antibody.	(4)

- D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, R. E. Chen, C. Havenar-Daughton, G. Snell, A. Telenti, H. W. Virgin, A. Lanzavecchia, M. S. Diamond, K. Fink, D. Veesler, D. Corti, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*. 583, 290–295 (2020).
- D. Zhou, H. M. E. Duyvesteyn, C.-P. Chen, C.-G. Huang, T.-H. Chen, S.-R. Shih, Y.-C. Lin, C.-Y. Cheng, S.-H. Cheng, Y.-C. Huang, T.-Y. Lin, C. Ma, J. Huo, L. Carrique, T. Malinauskas, R. R. Ruza, P. N. M. Shah, T. K. Tan, P. Rijal, R. F. Donat, K. Godwin, K. R. Buttigieg, J. A. Tree, J. Radecke, N. G. Paterson, P. Supasa, J. Mongkolsapaya, G. R. Screaton, M. W. Carroll, J. Gilbert-Jaramillo, M. L. Knight, W. James, R. J. Owens, J. H. Naismith, A. R. Townsend, E. E. Fry, Y. Zhao, J. Ren, D. I. Stuart, K.-Y. A. Huang, Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural & Molecular Biology.* 27, 950–958 (2020).
- 3. L. Piccoli, Y.-J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C. Silacci-Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A.

Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A. D. Marco, J. C. Nix, F. Mele, S. Jovic, B. F. Rodriguez, S. V. Gupta, F. Jin, G. Piumatti, G. L. Presti, A. F. Pellanda, M. Biggiogero, M. Tarkowski, M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, V. Lepori, E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, H. W. Virgin, A. Lanzavecchia, D. Corti, D. Veesler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell.* **183**, 1024-1042.e21 (2020).

- M. A. Tortorici, M. Beltramello, F. A. Lempp, D. Pinto, H. V. Dang, L. E. Rosen, M. McCallum, J. Bowen, A. Minola, S. Jaconi, F. Zatta, A. D. Marco, B. Guarino, S. Bianchi, E. J. Lauron, H. Tucker, J. Zhou, A. Peter, C. Havenar-Daughton, J. A. Wojcechowskyj, J. B. Case, R. E. Chen, H. Kaiser, M. Montiel-Ruiz, M. Meury, N. Czudnochowski, R. Spreafico, J. Dillen, C. Ng, N. Sprugasci, K. Culap, F. Benigni, R. Abdelnabi, S.-Y. C. Foo, M. A. Schmid, E. Cameroni, A. Riva, A. Gabrieli, M. Galli, M. S. Pizzuto, J. Neyts, M. S. Diamond, H. W. Virgin, G. Snell, D. Corti, K. Fink, D. Veesler, Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. *Science* (2020), doi:10.1126/science.abe3354.
- Y. Wu, F. Wang, C. Shen, W. Peng, D. Li, C. Zhao, Z. Li, S. Li, Y. Bi, Y. Yang, Y. Gong, H. Xiao, Z. Fan, S. Tan, G. Wu, W. Tan, X. Lu, C. Fan, Q. Wang, Y. Liu, C. Zhang, J. Qi, G. F. Gao, F. Gao, L. Liu, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science*. **368**, 1274–1278 (2020).
- C. O. Barnes, A. P. West, K. E. Huey-Tubman, M. A. G. Hoffmann, N. G. Sharaf, P. R. Hoffman, N. Koranda, H. B. Gristick, C. Gaebler, F. Muecksch, J. C. C. Lorenzi, S. Finkin, T. Hägglöf, A. Hurley, K. G. Millard, Y. Weisblum, F. Schmidt, T. Hatziioannou, P. D. Bieniasz, M. Caskey, D. F. Robbiani, M. C. Nussenzweig, P. J. Bjorkman, Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell*. **182**, 828-842.e16 (2020).
- B. Ju, Q. Zhang, J. Ge, R. Wang, J. Sun, X. Ge, J. Yu, S. Shan, B. Zhou, S. Song, X. Tang, J. Yu, J. Lan, J. Yuan, H. Wang, J. Zhao, S. Zhang, Y. Wang, X. Shi, L. Liu, J. Zhao, X. Wang, Z. Zhang, L. Zhang, Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 584, 115–119 (2020).
- R. Shi, C. Shan, X. Duan, Z. Chen, P. Liu, J. Song, T. Song, X. Bi, C. Han, L. Wu, G. Gao, X. Hu, Y. Zhang, Z. Tong, W. Huang, W. J. Liu, G. Wu, B. Zhang, L. Wang, J. Qi, H. Feng, F.-S. Wang, Q. Wang, G. F. Gao, Z. Yuan, J. Yan, A human neutralizing antibody targets the receptorbinding site of SARS-CoV-2. *Nature*. 584, 120–124 (2020).
- M. Yuan, H. Liu, N. C. Wu, C.-C. D. Lee, X. Zhu, F. Zhao, D. Huang, W. Yu, Y. Hua, H. Tien, T. F. Rogers, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, I. A. Wilson, Structural basis of a shared antibody response to SARS-CoV-2. *Science*. **369**, 1119–1123 (2020).

- N. K. Hurlburt, E. Seydoux, Y.-H. Wan, V. V. Edara, A. B. Stuart, J. Feng, M. S. Suthar, A. T. McGuire, L. Stamatatos, M. Pancera, Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *Nature Communications*. **11**, 5413 (2020).
- L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F.-W. Chan, V. Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*. 584, 450–456 (2020).
- N. C. Wu, M. Yuan, H. Liu, C.-C. D. Lee, X. Zhu, S. Bangaru, J. L. Torres, T. G. Caniels, P. J. M. Brouwer, M. J. van Gils, R. W. Sanders, A. B. Ward, I. A. Wilson, An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. *Cell Reports*. 33, 108274 (2020).



Figure S1. Glycosylation in SARS-CoV-2 spike protein RBD. Glycosylated residues are marked in blue, while the remainder of residues are colored by the number of epitopes that contain the residue (red color bar).



Figure S2. Relationship between the fraction of the population that receive a prophylactic that is completely effective in preventing infection from wild-type virus and the strength of selection for an escape mutant.



Number of infected individuals (millons)

Figure S3. Time required to establish a resistant viral single (**A**), double (**B**), triple (**C**), or quadruple (**D**) mutant with different fitness costs for intermediate mutants. In our model, viral variants with some, but not all, mutations required for resistance to an antibody intervention have a fitness cost (ranging from 1-9% less infectious). Increasing the fitness cost of these intermediates prolongs the time required for a resistant variant with a specific combination of 2-4 mutations (**B-D**) to establish in the population.